Arbovirus Testing Market Size - By Test Type (ELISA-based Tests, RT-PCR Based Tests), By End-use (Public Health Laboratory, Hospitals, Diagnostic Centers) – Global Forecast to 2032

Arbovirus Testing Market Size - By Test Type (ELISA-based Tests, RT-PCR Based Tests), By End-use (Public Health Laboratory, Hospitals, Diagnostic Centers) – Global Forecast to 2032

Arbovirus Testing Market Size

Arbovirus Testing Market size was valued at more than USD 1 billion in 2022 and is projected to reach over USD 1.9 billion by 2032 owing to rising prevalence rate of arthropod-borne viral diseases.
 

Arbovirus testing encompasses the diagnostic tests and related products used for the detection and identification of arboviruses. Arboviruses also known as arthropod-borne viruses is a group of viruses transmitted to humans primarily through the bites of infected ticks, mosquitoes, or other arthropods. These viruses can cause a wide range of diseases, including dengue fever, Zika virus infection, West Nile fever, and chikungunya, among others. Growing need for accurate and timely diagnosis of arbovirus infections to guide appropriate patient management and public health interventions will drive the overall industry growth potential.
 

Also, rising incidence of arthropod-borne viral diseases, advancements in diagnostic technologies, and government initiatives aimed at controlling and preventing arbovirus outbreaks are few aspects propelling market demand.
 

Growing research and development as well as adoption of advanced arbovirus testing technologies to enhance surveillance, outbreak response, and disease prevention strategies by several governments, health organizations, and researchers to combat arbovirus outbreak will boost market growth potential. For instance, in March 2022, World Health Organization (WHO) introduced global arbovirus initiative to combat emerging and re-emerging arboviruses having epidemic and pandemic potential in collaboration with the Immunization, Vaccines and Biologicals Department and the Department of Control of Neglected Tropical Diseases. This initiative aimed towards preparedness, monitor risk, detection and response, pandemic prevention and building a coalition of partners.
 

Further, continuous advancements in technologies such as molecular diagnostics, serological assays, and point-of-care testing for rapid and accurate detection of arboviruses leading to improved patient outcomes and public health interventions will thereby offer lucrative growth opportunities to the arbovirus testing market.
 

COVID-19 Impact

The COVID-19 pandemic had a significant impact on the arbovirus testing market. Owing to focus of healthcare institutions and resources moved to combatting the pandemic, testing and management of arbovirus infections became challenging. Surveillance and testing for arboviral infections were hampered due to overburdened healthcare systems and limited resources. Outbreak detection and response methods were redirected to COVID-19, causing delayed arbovirus testing. However, the pandemic highlighted the necessity of diagnostic testing and monitoring in the prevention and control of infectious diseases.
 

Arbovirus Testing Market Trends

The rising incidence of arbovirus infections such as dengue fever and zika virus infection due to climate change, urbanization and global travel are some of the major factors further augmenting the market expansion. For instance, according to the World Health Organization (WHO), 50-100 million cases of dengue fever, 500,000 cases of dengue haemorrhagic fever/ dengue shock syndrome and more than 20 000 deaths occur each year. This rise in arbovirus infections creating demand for accurate and timely diagnostic testing to facilitate early detection and appropriate patient management.
 

The surge in arbovirus cases leads to increasing focus on surveillance, prevention, and control measures, this will further accelerate the need for reliable and efficient arbovirus testing solutions. As a result, the market will experience substantial growth with advancements in diagnostic technologies and the development of new testing methods to meet the rising demand.
 

Arbovirus Testing Test Market Analysis

The arbovirus testing market by test type is segmented into RT-PCR based tests, ELISA-based tests, and others. The ELISA-based tests held the largest revenue size accounting for more than USD 530 million in 2022 and is estimated to witness significant growth over the forecasted timeline. The high revenue share is primarily attributable to the high focus on research and development activities and technological advancements in ELISA testing for detection of arbovirus disorders. Several innovations and continuous improvements in assay design, sensitivity, and specificity including development of multiplex ELISA assays for enhanced diagnostic efficiency and cost-effectiveness will offer substantial segmental growth potential.
 

Also, ELISA-based tests utilize in assessing the efficacy of vector control measures, identifying high-risk areas, and guiding targeted interventions that will bolster segment demand. Further, High investments in arbovirus surveillance programs and the availability of accurate and accessible ELISA-based tests are anticipated to propel segment revenue size.
 

The arbovirus testing market by end-use is categorized into hospitals, diagnostic centers, public health laboratory and others. Public health laboratory segment garnered highest revenue share in the year 2022 and is estimated to witness significant growth at 5.6% CAGR over the estimated timeframe. Expanding number of public health laboratories among several economies will boost the public health laboratory segment growth. Adoption of advanced diagnostic technologies for arbovirus testing such as rapid molecular assays, next-generation sequencing and high-throughput platforms that enable faster and more accurate detection of arboviruses in the facilities is anticipated to boost customer preference towards public health laboratory segment.
 

Further, Public health laboratories are actively collaborating with research institutions, diagnostic companies, and public health agencies to enhance their capabilities in arbovirus testing to promote knowledge sharing, standardization of testing protocols, and the development of new technologies leading to improved testing accuracy, efficiency, and harmonization across different laboratory settings. Such technological advancements will drive the public health laboratories growth potential.
 

U.S. arbovirus testing market accounted for over USD 400 million in 2022 and is estimated to witness substantial market growth over the forecast period.  The surge in incidence and prevalence of arbovirus diseases and booming geriatric population that are highly prone to viral diseases in the country are few factors accelerating market growth.
 

Furthermore, surge in point of care molecular diagnostics among clinical facilities, well-established healthcare infrastructure, growing R&D expenditures, high usage of sophisticated diagnostic tests and increase in healthcare spending will positively influence the market in the U.S. Also, establishment of comprehensive surveillance programs, strengthening of laboratory networks and the development of integrated response strategies to minimize arbovirus diseases will boost market demand in the U.S.
 

Arbovirus Testing Market Share

Some of the notable key industry players operating in the arbovirus testing market include

• Agilent Technologies Inc.
• Thermo Fisher Scientific
• NovaTec Immundiagnostica GmbH
• Euroimmun AG
• Abbott Laboratories
• DiaSorin SpA
• Bio-Rad
• Fluke Biomedical
• Copley Scientific
• Distek
• Becton
• Dickinson and Compan
• Merck KGaA
• F.Hoffmann La Roche Ltd.
• Siemens Healthineers AG
• QIAGEN N.V. 

. These market participants are implementing several growth strategies such as collaborations, partnerships, acquisitions & mergers, and new product development & launches to broaden their product portfolio as well as gain a competitive edge over others.
 

Arbovirus Testing Industry News

• In July 2022, Mylab announced launch of PathoDetect Extended Monsoon Fever Panel, a multiplex assay RT-PCR test kit for several monsoon disorders such as zika, malaria, dengue among others. These compact kits provide accurate results within 2 hours and also offers mass testing. This launch offered competitive edge to the company in the significant market.
   
•  In May 2022, Anitoa System introduced a portable RT-PCR molecular test in the U.S. This test kit comprised of Maverick qPCR instrument and used in detection of arbovirus disease especially dengue. Such product launches broadened company’s offerings in this significant market.
   

Arbovirus testing market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD from 2018 to 2032 for the following segments

Click here to Buy Section of this Report

By Test Type (USD Million)

• ELISA-based tests
• RT-PCR based tests
• Others

By End-use (USD Million)

• Hospitals
• Diagnostic Centers
• Public Health Laboratory
• Others

The above information is provided for the following regions and countries

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Belgium
  • The Netherlands
  • Switzerland
  • Poland
  • Sweden
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • New Zealand
  • Thailand
  • Singapore
  • Vietnam
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Chile
• Middle East & Africa
  • Saudi Arabia
  • South Africa
  • UAE